EHRA 24 - Investigator, Dr Boris Schmidt (Cardioangiologisches Centrum Bethanien, DE) is interviewed on ablation strategies for repeat procedures in patients with recurrent atrial fibrillation (AF).

The ASTRO trial is a multi-centre prospective randomized study that enrolled 256 patients with drug-refractory AF despite previous AF ablation. The trial showed no statistically significant differences between CB guided LAAI over LVA ablation in patients with AF despite durable PVI.

Interview Questions:

1. What is the reasoning behind this study?
2. What is the patient population and study design?
3. What are the key findings revealed at EHRA 24?
4. What are your key take-home messages?
5. How should these findings change practice?
6. What are the remaining questions?

Recorded on-site at EHRA in Berlin, 2024.

Support: This is an independent interview conducted by Radcliffe Cardiology.

Editors: Jordan Rance, Mirjam Boros 
Video Specialists: Oliver Miles, Dan Brent